Diabetes drug trial offers hope for rare gut disorder patients
NCT ID NCT07297238
Summary
This study is testing whether a GLP-1 medication (semaglutide), commonly used for diabetes, can help improve gut function in adults with short bowel syndrome who depend on intravenous nutrition. Twenty participants will receive either the medication or a placebo for four weeks alongside their standard care. Researchers will measure changes in gut barrier function, nutrient absorption, and whether patients can reduce their need for IV feeding.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTESTINAL FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jinling Hospital
Nanning, China, 210002, China
Conditions
Explore the condition pages connected to this study.